Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Amortizatization of Intangibles (2020 - 2025)

Nurix Therapeutics (NRIX) has disclosed Amortizatization of Intangibles for 6 consecutive years, with $2.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Amortizatization of Intangibles rose 466.57% to $2.5 million in Q4 2025 year-over-year; TTM through Nov 2025 was $10.1 million, a 42.28% increase, with the full-year FY2025 number at $10.1 million, up 42.28% from a year prior.
  • Amortizatization of Intangibles was $2.5 million for Q4 2025 at Nurix Therapeutics, down from $3.0 million in the prior quarter.
  • In the past five years, Amortizatization of Intangibles ranged from a high of $4.4 million in Q4 2021 to a low of -$2.7 million in Q3 2021.
  • A 5-year average of $1.6 million and a median of $1.5 million in 2022 define the central range for Amortizatization of Intangibles.
  • Biggest YoY gain for Amortizatization of Intangibles was 9375.0% in 2021; the steepest drop was 3245.0% in 2021.
  • Nurix Therapeutics' Amortizatization of Intangibles stood at $4.4 million in 2021, then plummeted by 67.71% to $1.4 million in 2022, then soared by 38.79% to $2.0 million in 2023, then crashed by 134.81% to -$685000.0 in 2024, then soared by 466.57% to $2.5 million in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Amortizatization of Intangibles are $2.5 million (Q4 2025), $3.0 million (Q3 2025), and $2.9 million (Q2 2025).